Publications by authors named "Joseph K Mbuthia"
Article Synopsis
- Antiretroviral therapy for children under 3 years with HIV often uses a liquid formulation of lopinavir/ritonavir (LPV/r), but it has taste issues and requires refrigeration, which led to the development of LPV/r oral pellets that can be mixed with food and don't need cooling.
- The study assessed the drug exposure of these LPV/r oral pellets in Kenyan and Ugandan children using pharmacokinetic modeling to understand how body weight affects drug clearance and effectiveness.
- Analysis of data from 514 children indicated that the pellets achieved the desired drug levels across different weight bands as defined by the World Health Organization, suggesting they are a suitable treatment option for young children with HIV.
Abacavir Drug Exposures in African Children Under 14 kg Using Pediatric Solid Fixed Dose Combinations According to World Health Organization Weight Bands.
J Pediatric Infect Dis Soc
November 2023
Background: The pharmacokinetics of abacavir (ABC) in African children living with HIV (CLHIV) weighing <14 kg and receiving pediatric fixed dose combinations (FDC) according to WHO weight bands dosing are limited. An ABC population pharmacokinetic model was developed to evaluate ABC exposure across different World Health Organization (WHO) weight bands.
Methods: Children enrolled in the LIVING study in Kenya and Uganda receiving ABC/lamivudine (3TC) dispersible tablets (60/30 mg) according to WHO weight bands.
To evaluate protective antibody levels against hepatitis B surface antigen in HIV-infected and HIV-uninfected Kenyan children, this study enrolled 531 children. In the HIV-infected group, only 18.3% had protective hepatitis B surface antigen compared with 74.
View Article and Find Full Text PDF